	www.hiv-druginteractions.org		UNIVERSITY OF LIVERPOOL
		Interaction Report	
Report ID:			

 Date Produced:
 20 April 2025

 Antiretroviral Treatment
 Co-medications

 Efavirenz (EFV)
 Alprazolam

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Efavirenz (EFV) + Alprazolam

Coadministration has not been studied. Alprazolam is metabolised mainly by CYP3A4. Efavirenz, an inducer of CYP3A4, could potentially decrease alprazolam exposure. Monitor clinical effect and withdrawal symptoms.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

The report is provided for information only. It is not intended to replace a consultation with an appropriately qualities that have possible intended to provide a screatility metal to the provide intended to replace a consultation with an appropriately qualities that have possible intended to provide a screatility metal to the provide intended to replace a consultation with an appropriately qualities that have possible intended to provide a screatility metal to the provide intended to provide a screatility metal to the provide intended to provide a screatility metal to the provide a screatility of the provide a screatility metal to the provide a screatility of the provide a screatility metal to the provide a screatility of the screatility metal to the screatility of the scr